Henrik Hager, Pathologist and Clinical Associate Professor
Center of Clinical Pathology at Vejle Hospital
”Immunotherapy is currently a popular and effective method for treating lung cancer. Unfortunately, it can be difficult to follow the effect of the treatment, especially in the beginning, where the tumour progression cannot be monitored using x-ray as with traditional chemotherapy and radiation therapy. Thus, we are searching for valid and suitable clinical biomarkers, that will allow us to non-invasively monitor the effect of the treatment i.e. in blood and bronchial secretions. These new protein screening panels have an enormous potential, as targeted biomarker analysis will enable us to perform broad analyses of immune proteins and monitor how the treatment affects their up and down regulation.”